TNFα-induced MUC4 elicits trastuzumab resistance in ErbB-2-positive breast cancer

被引：0
|
作者：
Mercogliano, Maria F. [1 ]
De Martino, Mara [1 ]
Venturutti, Leandro [1 ]
Rivas, Martin A. [2 ]
Inurrigarro, Gloria [3 ]
Frahm, Isabel [3 ]
Proietti, Cecilia J. [1 ]
Izzo, Franco [1 ]
Elizade, Patricia V. [1 ]
Schillaci, Roxana [1 ]
机构：
[1] IBYME CONICET, CABA, Buenos Aires, DF, Argentina
[2] Weill Cornell Med Coll, New York, NY USA
[3] Sanatorio Mater Dei, Serv Patol, CABA, Buenos Aires, DF, Argentina
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-712
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
712
引用
收藏
页数：2
相关论文
共 50 条
  • [1] TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
    Mercogliano, Maria F.
    De Martino, Mara
    Venturutti, Leandro
    Rivas, Martin A.
    Proietti, Cecilia J.
    Inurrigarro, Gloria
    Frahm, Isabel
    Allemand, Daniel H.
    Gil Deza, Ernesto
    Ares, Sandra
    Gercovich, Felipe G.
    Guzman, Pablo
    Roa, Juan C.
    Elizalde, Patricia V.
    Schillaci, Roxana
    CLINICAL CANCER RESEARCH, 2017, 23 (03) : 636 - 648
  • [2] BLOCKING SOLUBLE TNFα SENSITIZES HER2-POSITIVE BREAST CANCER TO TRASTUZUMAB THROUGH MUC4 DOWNREGULATION AND SUBVERTS IMMUNOSUPPRESSION
    Bruni, Sofia
    De Martino, Mara
    Mauro, Florencia
    Mercogliano, Maria
    Proietti, Cecilia
    Cordo-Russo, Rosalia
    Elizalde, Patricia
    Schillaci, Roxana
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A914 - A914
  • [3] Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression
    Bruni, Sofia
    Mauro, Florencia L.
    Proietti, Cecilia J.
    Cordo-Russo, Rosalia, I
    Rivas, Martin A.
    Inurrigarro, Gloria
    Dupont, Agustina
    Rocha, Dario
    Fernandez, Elmer A.
    Gil Deza, Ernesto
    Lopez Della Vecchia, Daniel
    Barchuk, Sabrina
    Figurelli, Silvina
    Lasso, David
    Friedrich, Adrian D.
    Santilli, Maria C.
    Regge, Maria, V
    Lebersztein, Gabriel
    Levit, Claudio
    Anfuso, Fabiana
    Castiglione, Teresa
    Elizalde, Patricia, V
    Mercogliano, Maria F.
    Schillaci, Roxana
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (03)
  • [4] PKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance
    Pandya, Kinnari
    Wyatt, Debra
    Gallagher, Brian
    Shah, Deep
    Baker, Andrew
    Bloodworth, Jeffrey
    Zlobin, Andrei
    Pannuti, Antonio
    Green, Andrew
    Ellis, Ian O.
    Filipovic, Aleksandra
    Sagert, Jason
    Rana, Ajay
    Albain, Kathy S.
    Miele, Lucio
    Denning, Mitchell F.
    Osipo, Clodia
    CLINICAL CANCER RESEARCH, 2016, 22 (01) : 175 - 186
  • [5] Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?
    Rosalía I. Cordo Russo
    María F. Chervo
    Santiago Madera
    Eduardo H. Charreau
    Patricia V. Elizalde
    Hormones and Cancer, 2019, 10 : 64 - 70
  • [6] Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?
    Cordo Russo, Rosalia I.
    Chervo, Maria F.
    Madera, Santiago
    Charreau, Eduardo H.
    Elizalde, Patricia V.
    HORMONES & CANCER, 2019, 10 (2-3): : 64 - 70
  • [7] Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer
    María F. Mercogliano
    Gloria Inurrigarro
    Mara De Martino
    Leandro Venturutti
    Martín A. Rivas
    Rosalía Cordo-Russo
    Cecilia J. Proietti
    Elmer A. Fernández
    Isabel Frahm
    Sabrina Barchuk
    Daniel H. Allemand
    Silvina Figurelli
    Ernesto Gil Deza
    Sandra Ares
    Felipe G. Gercovich
    Eduardo Cortese
    Matías Amasino
    Pablo Guzmán
    Juan C. Roa
    Patricia V. Elizalde
    Roxana Schillaci
    BMC Cancer, 17
  • [8] Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer
    Mercogliano, Maria F.
    Inurrigarro, Gloria
    De Martino, Mara
    Venturutti, Leandro
    Rivas, Martin A.
    Cordo-Russo, Rosalia
    Proietti, Cecilia J.
    Fernandez, Elmer A.
    Frahm, Isabel
    Barchuk, Sabrina
    Allemand, Daniel H.
    Figurelli, Silvina
    Deza, Ernesto Gil
    Ares, Sandra
    Gercovich, Felipe G.
    Cortese, Eduardo
    Amasino, Matias
    Guzman, Pablo
    Roa, Juan C.
    Elizalde, Patricia V.
    Schillaci, Roxana
    BMC CANCER, 2017, 17
  • [9] Inhibition of erbB-2-positive breast cancer cell growth by erbB-2 antisense oligonucleotides
    Liu, XJ
    Pogo, BGT
    ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1996, 6 (01): : 9 - 16
  • [10] Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas
    Ilianna Zoi
    Michalis V. Karamouzis
    Evangelia Xingi
    Panagiotis Sarantis
    Dimitra Thomaidou
    Panayiotis Lembessis
    Stamatios Theocharis
    Athanasios G. Papavassiliou
    Breast Cancer Research, 21
12345